Previous Close | 37.69 |
Open | 37.63 |
Bid | 37.36 x 900 |
Ask | 53.99 x 800 |
Day's Range | 37.26 - 37.76 |
52 Week Range | 21.70 - 41.65 |
Volume | 165,128 |
Avg. Volume | 354,084 |
Market Cap | 1.7B |
Beta (5Y Monthly) | 2.36 |
PE Ratio (TTM) | 207.94 |
EPS (TTM) | 0.18 |
Earnings Date | Feb 19, 2020 - Feb 24, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 49.00 |
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that the FDA in a letter dated December 6, 2019, stated that it has determined that STAAR has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN® Implantable Collamer® Lens for Myopia, and EVO/EVO+ VISIAN® Toric Implantable Collamer® Lens for Myopia with Astigmatism.
Q3 2019 STAAR Surgical Co Earnings Call
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today that the Company will host an Investor and Analyst Day on Friday, November 8, 2019 in New York City at 8:30 a.m. EST. A webcast with accompanying slides of a presentation by Caren Mason, President and CEO of STAAR Surgical, and a presentation by Dr. Mark Packer will be available on the “Investors” page of the Company's website at https://www.staar.com/.
Staar Surgical (STAA) delivered earnings and revenue surprises of 33.33% and 4.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
STAAR Surgical Company , a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended September 27, 2019.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that Dr. Jorn S. Jorgensen successfully implanted the Company’s EVO Visian ICL in his son, Jannik Jorgensen, during a live-streamed event which also celebrated the opening of EuroEyes’ newest clinic. Dr. Jorgensen is the founder, chairman, executive director and CEO of the EuroEyes clinic group, with clinics across Germany, Denmark and China.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 27, 2019 on Wednesday, October 30, 2019 after the market close. STAAR will host a conference call and webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 7170127), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.
Attractive stocks have exceptional fundamentals. In the case of STAAR Surgical Company (NASDAQ:STAA), there's is a...
Today we'll look at STAAR Surgical Company (NASDAQ:STAA) and reflect on its potential as an investment. To be precise...
Q2 2019 STAAR Surgical Co Earnings Call
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Great second-quarter earnings results sent the implantable contact lens maker's stock into orbit.
STAA earnings call for the period ending June 30, 2019.
Staar Surgical (STAA) delivered earnings and revenue surprises of 40.00% and -1.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
In 2015 Caren Mason was appointed CEO of STAAR Surgical Company (NASDAQ:STAA). First, this article will compare CEO...